Lakefront Biotherapeutics (LKFT) Insider & Congress Trades

Smart money at a glance

Filings to Nov 14, 2026

No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersForm 4, 90 days: $0
CongressSTOCK Act, 180 days: None
Big funds13F, latest quarter: No large changes
Federal contractsUSAspending.gov, 12 months: No awards

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

Unlock the full results

Questions about LKFT filings

Are insiders buying or selling Lakefront Biotherapeutics NV (LKFT) stock?

Neither. Lakefront Biotherapeutics NV (LKFT) insiders filed no open-market purchases or sales in the 90 days to Nov 14, 2026, according to SEC Form 4 filings.

Which members of Congress have traded LKFT recently?

None. No member of Congress disclosed a LKFT trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this LKFT smart-money data?

This summary uses filings available on Nov 14, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.

No recent filings found.

Questions about LKFT filings

Are insiders buying or selling Lakefront Biotherapeutics NV (LKFT) stock?

Neither. Lakefront Biotherapeutics NV (LKFT) insiders filed no open-market purchases or sales in the 90 days to Nov 14, 2026, according to SEC Form 4 filings.

Which members of Congress have traded LKFT recently?

None. No member of Congress disclosed a LKFT trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this LKFT smart-money data?

Checking federal contract awards

Unlock everything for $29/month

Unlock for $29/month

Reported Mar 26, 2026

Results versus expectations

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Mar 26, 2026

Period ending

Dec 31, 2025

Earnings per share

Unavailable

EPS comparison unavailable

Revenue (FY)

EUR 1.11B

Year ended Dec 31, 2025 · SEC filing

Next report

What the street expects next

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Dec 31, 2025Reported Mar 26, 2026	Not on file	No estimate	EUR 1.11B · FYSEC filing	No year-ago quarter
Jun 30, 2021Reported Aug 5, 2021	Not on file	No estimate	EUR 139.8MSEC filing	+40.4%from EUR 99.6M
Jun 30, 2020Reported Aug 5, 2021	Not on file	No estimate	EUR 99.6MSEC filing	+69.5%from EUR 58.7M
Jun 30, 2019Reported Aug 6, 2020	Not on file	No estimate	EUR 58.7MSEC filing	+18.2%from EUR 49.7M
Jun 30, 2018Reported Jul 25, 2019	Not on file	No estimate	EUR 49.7MSEC filing	+84.4%from EUR 26.9M
Jun 30, 2017Reported Aug 2, 2018	Not on file	No estimate	EUR 26.9MSEC filing	No year-ago quarter

Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.

Open: $32.99
High: $33.42
Low: $32.95
Prev close: $33.41
52-wk high: $36.24
52-wk low: $25.68
Mkt cap: $2.20B
P/E: 3.2x
ROE: +20.1%
Fwd P/E: 344.8x
Beta: 0.01
P/S: 2.2x
P/B: 0.6x
Profit margin: +60.2%
Op margin: +57.5%

Fundamentals

Is the business strong?

Fairly priced and profitable.

Net margin: 60.2%
P/E: 3.17
Forward P/E: 344.83
Market cap: $2.2B

Valuation

P/S2.22
P/B0.61

Quality

Operating margin57.5%
ROE20.1%
ROA9.9%

Growth

Beta0.01

Technicals

Price structure

This stock is in a strong uptrend, and looks overbought after a fast run-up.

Trend

Strong uptrend

85 / 100

RSI 14

73overbought

20D volatility

26%annualized

52-week range

$33.34

$25.68$36.24

20D support

$29.36recent floor

20D resistance

$34.49recent ceiling

Returns

5D -2.2%20D +13.4%60D +19.1%

Price vs moving averages

SMA20 +4.2%SMA50 +10.5%SMA200 +11.6%

Volume pace

0.74xvs prior 20D

Quarter / reported

Earnings per share

Beat or miss

Revenue / income

Revenue vs last year

Dec 31, 2025Mar 26, 2026

Not on file

No estimate

EUR 1.11B · FYSEC filing

No year-ago quarter

Jun 30, 2021Aug 5, 2021

Not on file

No estimate

EUR 139.8MSEC filing

+40.4%from EUR 99.6M

Jun 30, 2020Aug 5, 2021

Not on file

No estimate

EUR 99.6MSEC filing

+69.5%from EUR 58.7M

Jun 30, 2019Aug 6, 2020

Not on file

No estimate

EUR 58.7MSEC filing

+18.2%from EUR 49.7M

Jun 30, 2018Jul 25, 2019

Not on file

No estimate

EUR 49.7MSEC filing

+84.4%from EUR 26.9M

Jun 30, 2017Aug 2, 2018

Not on file

No estimate

EUR 26.9MSEC filing

No year-ago quarter

Lakefront Biotherapeutics NV

Smart money at a glance

What do analysts expect?

Questions about LKFT filings

Questions about LKFT filings

How top traders are positioned

Unlock everything for $29/month

Results versus expectations

What the street expects next

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

Lakefront Biotherapeutics NV

Smart money at a glance

What do analysts expect?

Questions about LKFT filings

Questions about LKFT filings

How top traders are positioned

Unlock everything for $29/month

Results versus expectations

What the street expects next

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

Lakefront Biotherapeutics NV

Overview

Questions about LKFT filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.

Lakefront Biotherapeutics NV

Overview

Questions about LKFT filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.